MedTrace Logo

Assessment of Combined Praziquantel and Albendazole vs Albendazole Alone to Treat Active Parenchymal Neurocysticercosis

NCT06376396 · Status: NOT_YET_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2024-04-23

No results posted yet for this study

Summary

The goal of this clinical trial is to compare the combination albendazole and praziquantel versus albendazole alone in patients affected by neurocysticercosis.

Conditions

  • Neurocysticercosis

Interventions

DRUG

albendazole and praziquantel

Combination of albendazole plus praziquantel

DRUG

Albendazole

Albendazole alone

Sponsors & Collaborators

  • Muhimbili University of Health and Allied Sciences

    collaborator OTHER

  • National Institute for Medical Research, Tanzania

    collaborator OTHER_GOV

  • Sokoine University of Agriculture

    collaborator OTHER

  • University of Zambia

    collaborator OTHER

  • University Ghent

    collaborator OTHER

  • R-Evolution Worldwide S.r.l. Impresa Sociale

    lead OTHER

Principal Investigators

  • Kabemba E. Mwape, Prof. · University of Zambia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-30
Primary Completion
2025-12-31
Completion
2026-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06376396 on ClinicalTrials.gov